Hemoglobinopathy Treatment Drugs Market, by Drug Type (Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, and Others), by Disease Type (Thalassemia, Sickle Cell Disease, and Other Hb Variants Diseases), by Distribution Channel (Hospitals Pharmacies, Re

Hemoglobinopathy Treatment Drugs Market, by Drug Type (Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, and Others), by Disease Type (Thalassemia, Sickle Cell Disease, and Other Hb Variants Diseases), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hemoglobinopathy is a group of hereditary blood disorders involving an abnormality in the structure of hemoglobin. These disorders include both sickle cell disease (SCD) and thalassemia. Common symptoms of the condition include severe pain, shortness of breath, enlarged spleen, and growth problems in children. Other types of hemoglobinopathies linked to the structural hemoglobin variants are HbS, HbE, and HbC. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Drugs to treat the symptoms of hemoglobinopathy include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. According to the data of National Center for Biotechnology Information, more than 90% of patients currently survive the adulthood. Optimally treated patients have a projected life span of 50 to 60 years.
Market Dynamics
Increasing incidence and prevalence of sickle cell disease (SCD) is expected to propel growth of the global hemoglobinopathy treatment drugs market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in October 2021, SCD affects around 100,000 Americans every year. Moreover, as per the same source, around 1 in 13 African-American babies are born with sickle cell trait (SCT).
However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2021, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints. Moreover, high costs, and difficulties associated with diagnosis of hemoglobinopathies such as lack of proper knowledge and lack of skilled professionals are expected to restrain growth of the market up to certain extent.
Key features of the study:
This report provides in-depth analysis of the global hemoglobinopathy treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Inc., Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hemoglobinopathy treatment drugs market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Hemoglobinopathy Treatment Drugs Market, By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
Global Hemoglobinopathy Treatment Drugs Market, By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hemoglobinopathy Treatment Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC Countries
Israel
Rest of Middle East
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Bristol-Myers Squibb Company*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlycoMimetics Inc.
Pfizer Inc.
Anthera Pharmaceuticals Inc.
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company Ltd.
Novartis International AG
Bluebird Bio Inc.
HemaQuest Pharmaceuticals Inc.
Emmaus Medical Inc.
Baxter International Inc.
Prolong Pharmaceuticals
Medunik USA Inc.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics, Inc.
Alnylam Pharmaceuticals
Acceleron Pharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.